JAK1 and parasitic infectious disease: Given the wealth of data on JAK2 inhibitors and the fact that one such inhibitor, Ruxolitinib (targets JAK1/2) has a European Union patent that is expected to expire in August 2027 and the US patent is expected to expire in December 2027 offers opportunity for use in parasitic disease treatment.